Our Cardiovascular Scene Investigation team consisting of young physicians and researchers, discussed novel developments with experts during the latest ESC congress.
CSI Rome Terje Pedersen defended the 'contra'-argument in a discussion on the use of PCSK9 inhibitors in current clinical practice. He explains to Lotte Koopal and Gijs Berkelmans that while being involved in clinical studies of a PCSK9 antibody, he is still comfortable in the contra-position.
CSI Rome Kausik Ray was involved in a project which investigated in UK databases which proportion of the predicted population with FH has been identified and is labelled as such. Johanneke van den Berg and Corien Flint discuss the consequences of underdetection with him, and how this may be improved.
CSI Rome Nicole Jaspers en Gijs Berkelmans discuss the role of precision medicine in secondary prevention with Dr. Noel Bairey Merz, as well as which approaches and types of data can be considered to assess risk.
CSI Rome Analysis of ApoB levels in the NHANES population revealed that guideline recommended ApoB targets have limited value in clinicial practice. Lotte Koopal and Gijs Berkelmans discuss these insights with Dr. Seth Shay Martin and Dr. Allan Sniderman.
CSI Rome Guido Kranenberg studied the potential impact of bisphosphonate on calcification of the arterial intima media. He shares the findings of a systematic review and meta-analysis with Nicole Jaspers and they discuss which other studies might shed light on this relationship.
CSI Rome Robert Horne is a Professor of Behavioural Medicine at University College London, United Kingdom who studies treatment non-adherence. Monique van Kleef discusses with him why this is a particular problem in hypertension, and how this may be improved.
CSI Rome Manon Slob and Shahnam Sharif extensively discuss the results of the EMPA-REG OUTCOME study, the first outcomes trial with an SGLT2 inhibitor, with Prof. Silvio Inzucchi, including what the results may mean for the management of diabetes.
CSI ROME Nicolette van der Sande and Monique van Kleef question Wilko Spiering about the interim results of the CALM-FIM study. This was a first-in-man study with a new device (MobiusHD) for patients with treatment resistant hypertension.
CSI ROME Nicole Jaspers and Manon Slob interview Prof. Paul Ridker about the concept of residual risk and how the different forms may be targeted with novel therapeutic strategies to further lower CV risk.
CSI ROME Nicolette van der Sande and Monique van Kleef critically discuss the SPRINT trial results with William Cushman and Sverre Kjeldsen. The professors disagree on whether these results should influence new guidelines.